AR060565A1 - Vacuna para la gripe aviaria y metodos de uso - Google Patents

Vacuna para la gripe aviaria y metodos de uso

Info

Publication number
AR060565A1
AR060565A1 ARP070101721A ARP070101721A AR060565A1 AR 060565 A1 AR060565 A1 AR 060565A1 AR P070101721 A ARP070101721 A AR P070101721A AR P070101721 A ARP070101721 A AR P070101721A AR 060565 A1 AR060565 A1 AR 060565A1
Authority
AR
Argentina
Prior art keywords
methods
vaccine
aviary
flu
vaccines
Prior art date
Application number
ARP070101721A
Other languages
English (en)
Spanish (es)
Original Assignee
Dow Agrosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc
Publication of AR060565A1 publication Critical patent/AR060565A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP070101721A 2006-04-21 2007-04-20 Vacuna para la gripe aviaria y metodos de uso AR060565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79380406P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
AR060565A1 true AR060565A1 (es) 2008-06-25

Family

ID=39402309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101721A AR060565A1 (es) 2006-04-21 2007-04-20 Vacuna para la gripe aviaria y metodos de uso

Country Status (9)

Country Link
US (1) US7993655B2 (enExample)
EP (1) EP2010210A4 (enExample)
JP (1) JP2009535306A (enExample)
KR (1) KR20080109094A (enExample)
CN (1) CN101578111A (enExample)
AR (1) AR060565A1 (enExample)
BR (1) BRPI0710689A2 (enExample)
CA (1) CA2650091A1 (enExample)
WO (1) WO2008060669A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540801A (ja) * 2006-06-16 2009-11-26 ダウ・アグロサイエンス・エル・エル・シー トリインフルエンザ赤血球凝集素の新規なｄｎａ配列、ベクターおよびタンパク質
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
KR20100006574A (ko) 2007-05-30 2010-01-19 사무엘 보고치 수산 양식되는 무척추동물의 병원체 감염에 대항하는 합성 레플리킨 펩티드
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
SG187500A1 (en) * 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
DK2294202T3 (en) 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
SG10201401532PA (en) * 2009-04-23 2014-08-28 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
SI2445928T1 (en) 2009-06-24 2018-05-31 Medicago Inc. HYPER PARTICULARS, SIMILAR VIRUSES OF GRIPE, WHICH HAVE EXPOSED HEMAGLUTININE
SG178918A1 (en) 2009-09-22 2012-04-27 Medicago Inc Method of preparing plant-derived vlps
EP2515661A4 (en) * 2009-12-23 2013-11-13 Vaxgene Corp IMMUNE PROTECTION THROUGH ORAL ADMINISTRATION OF MINI-CAPSULES WITH RECOMBINANT LACTOCOCCUS LACTIS
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
WO2013013075A2 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
AU2013204906B2 (en) * 2012-03-12 2016-01-07 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
AU2013359146B2 (en) 2012-12-13 2017-12-07 Corteva Agriscience Llc DNA detection methods for site specific nuclease activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885248A (en) 1984-02-15 1989-12-05 Lubrizol Genetics, Inc. Transfer vector
US5173410A (en) 1984-02-15 1992-12-22 Lubrizol Genetics Inc. Transfer vector
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
ATE108828T1 (de) 1987-02-09 1994-08-15 Lubrizol Genetics Inc Hybrides rns-virus.
WO1991009957A1 (en) 1989-12-22 1991-07-11 E.I. Du Pont De Nemours And Company Site-specific recombination of dna in plant cells
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
JPH07200893A (ja) 1993-12-27 1995-08-04 Toshiba Corp 自動精算機
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
JP2000253876A (ja) * 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US6855536B2 (en) 2000-07-20 2005-02-15 University Of Tennessee Research Corp., Inc. Materials and methods for the enhancement of effective root nodulation in legumes
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
DE10061150A1 (de) 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10109354A1 (de) 2001-02-27 2002-09-05 Icon Genetics Ag Rekombinante virale Schaltersysteme
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
CN1533438A (zh) 2001-06-08 2004-09-29 �����Ŵ��Ƽ���˾ 在植物生产蛋白质的方法
DE10129010A1 (de) 2001-06-13 2002-12-19 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10143205A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Verfahren zur Proteinproduktion in Pflanzen
ES2329450T3 (es) 2002-04-29 2009-11-26 Icon Genetics Gmbh Proceso para producir organismos transgenicos ambientalmente seguros.
NZ542933A (en) * 2003-05-05 2009-08-28 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
DE602004027403D1 (de) 2003-11-10 2010-07-08 Icon Genetics Ag Von rna-virus abgeleitetes pflanzenexpressionssystem

Also Published As

Publication number Publication date
EP2010210A2 (en) 2009-01-07
US20090136532A1 (en) 2009-05-28
WO2008060669A2 (en) 2008-05-22
KR20080109094A (ko) 2008-12-16
CA2650091A1 (en) 2008-05-22
WO2008060669A3 (en) 2009-05-07
US7993655B2 (en) 2011-08-09
BRPI0710689A2 (pt) 2012-02-22
CN101578111A (zh) 2009-11-11
JP2009535306A (ja) 2009-10-01
EP2010210A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
WO2008060669A3 (en) Vaccine for avian influenza and methods of use
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
CR9551A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
MX2018009917A (es) Vacuna contra el virus del zika.
MX2011000047A (es) Uso de factores de crecimiento recombinantes derivados de plantas en el cuidado de la piel.
MX381718B (es) Agentes biologicos y su uso en plantas.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
IT1397734B1 (it) Uso di estratti naturali di tannini e non tannini atti a migliorare la fertilita' del suolo e determinare un effetto starter sulle colture, e fitocomplesso di tannini e di non tannini per tale uso.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
EA201070219A1 (ru) Полимерные мультиэпитопные вакцины против гриппа
CL2008002727A1 (es) Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos
UY36395A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
GT201100145A (es) Vacuna recombinante para influenza aviar y sus usos
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
CL2013001853A1 (es) Bacteria no patogena gram negativa perteneciente a la clase betaproteobacteria y subfamilia neisseriaceae; extracto que la comprende; composicion que comprende a la bacteria o al extracto; y su uso para tratar o prevenir trastornos inflamatorios dermatologicos.
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal